雷公藤多苷对自身免疫性甲状腺炎大鼠模型外周血CXCR3、CCR4基因表达的影响

摘要/Abstract

摘要：

目的分析雷公藤多苷对实验性自身免疫性甲状腺炎大鼠外周血单一核细胞中CXCR3、CCR4基因表达的影响，探讨其调节Th1/Th2平衡的可能机制。方法清洁级雌性Wistar大鼠20只，建立实验性自身免疫性甲状腺炎动物模型，随机分成两组，对照组与雷公藤组，分别每天给予生理氯化钠溶液、雷公藤多苷片悬液5.5 mg/kg灌胃治疗。4周后处死大鼠，提取外周血单一核细胞，抽提RNA并反转录成cRNA，以Th1-Th2-Th3微点阵基因芯片及实时RT-PCR方法检测CXCR3、CCR4基因表达差异。结果与实验性自身免疫性甲状腺炎大鼠对照组相比较，雷公藤多苷片治疗组外周血单一核细胞中CXCR3表达明显下降（雷公藤多苷片组和对照组分别为0.52 ± 0.10和1.05 ± 0.17，P ＜ 0.01），而CCR4明显升高（分别为1.56 ± 0.13和1.02 ± 0.09，P ＜ 0.01），CXCR3/CCR4比值明显低于对照组（分别为0.39 ± 0.22和1.04 ± 0.12，P ＜ 0.01）。结论雷公藤多苷可能通过降低CXCR3、升高CCR4来调节实验性自身免疫性甲状腺炎大鼠体内Th1、Th2细胞及其细胞因子的比例，从而达到调节Th1/Th2平衡的目的。

关键词: 雷公藤多甙, 实验性自身免疫性甲状腺炎, Th1, Th2, 基因芯片, CXCR3, CCR4

Abstract:

Objective To analyze the impact of tripterygium glycosides （TG） on the expression of CXCR3 and CCR4 gene in peripheral blood mononuclear cells from experimental autoimmune thyroiditis （EAT） rats, and to explore the possible mechanism for regulation of Th1/Th2 balance by TG. Methods EAT was induced in 20 rats, which were randomly divided into two groups, i.e., control group and TG group, to receive intragastric physiological saline and TG suspension （5.5 mg/kg） daily, respectively. The rats were killed 4 weeks later, and total RNA was extracted from the peripheral blood mononuclear cells of rats and used for cRNA synthesis. The gene expressions of CXCR3 and CCR4 were detected with a Th1-Th2-Th3 microarray gene chip and realtime RT-PCR. Results Compared with the control group, there was a significant decrease in the mRNA expression of CXCR3 （0.52 ± 0.10 vs. 1.05 ± 0.17, P ＜ 0.01） and CXCR3/CCR4 ratio （0.39 ± 0.22 vs. 1.04 ± 0.12, P ＜ 0.01) in the TG group, together with an increase in the mRNA expression of CCR4 （1.56 ± 0.13 vs. 1.02 ± 0.09, P ＜ 0.01）. Conclusions TG could regulate the number of Th1 and Th2 cells as well as their cytokine expression ratio likely by reducing CXCR3 and enhancing CCR4 expression, so as to modulate the Th1/Th2 balance in EAT rats.

Key words: Tripterygium Wilfordii Polyglycoside, experimental autoimmune thyroiditis, Th1, Th2, gene chip, CXCR3, CCR4

徐晓光张红顾军. 雷公藤多苷对自身免疫性甲状腺炎大鼠模型外周血CXCR3、CCR4基因表达的影响[J]. 中华皮肤科杂志, 2010, 43(11): 792-795.

参考文献

[1] 闫衡. 皮肤病的Th1/Th2模式. 国外医学皮肤性病学分册，2001，27(5)：274~276. [2] Phenekos C, Vryonidou A, Gritzapis AD, et al. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation, 2004, 11(4): 209~213. [3] Sa EH, Jin UH, Kim DS, et al. Herbal medicine Gamgungtang down-regulates autoimmunity through induction of TH2 cytokine production by lymphocytes in experimental thyroiditis model. J Ethnopharmacol, 2007, 109(3): 472~479. [4] Choi EW, Shin IS, Lee CW, et al. The effect of gene therapy using CTLA4Ig/ silica- nanoparticles on canine experimental autoimmune thyroiditis. J Gene Med, 2008, 10(7): 795~804. [5] 张红，徐晓光，顾军. 不同抗银屑病药物对实验性动物Th1/Th2基因表达的影响. 中国皮肤性病学杂志，2008，22（3）：140～145. [6] Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol, 2001, 98 (1): 39~45. [7] Giustizieri ML, Mascia F, Frezzolini A, et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol, 2001, 107 (5): 871~877. [8] Goebeler M, Toksoy A, Spandau U, et al. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol, 1998, 184(1): 89~95. [9] Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol, 2001, 194 (4): 398~405. [10] García-López MA, Sancho D, Sánchez-Madrid F, et al. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab, 2001, 86(10): 5008~5016. [11] Romagnani P, Rotondi M, Lazzeri E, et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves′ disease. Am J Pathol, 2002, 161(1): 195~206. [12] McColl SR, Mahalingam S, Staykova M, et al. Expression of rat I-TAC/ CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands. Lab Invest, 2004, 84(11): 1418~1429. [13] Matsumo Y, Sakuma H, Miyakoshi A, et al. Characterization of relapsing autoimmune encephalomyelitis and its treatment with decoy chemokine receptor genes. J Neuroimmunol, 2005, 170(22): 49~61. [14] Wildbaum G, Netzer N, Karin N, et al. Plasmid DNA encoding IFN-gamma inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephal omyelitis. J Immunol, 2002, 168(11): 5885~5892. [15] Hase K, Tani K, Shimizu T, et al. Increased CCR4 expression in active systemic lupus erythematosus. J Leukoc Biol, 2001, 70(5): 749~755. [16] Nakatani T, Kaburagi Y, Shimada Y, et al. CCR4 memory CD4+ T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol, 2001, 107(2): 353~358. [17] Orlikowski D, Chazaud B, Plonquet A, et al. Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain–Barré syndrome and experimental autoimmune neuritis. J Neuroimmunol, 2003, 134(1-2):118~127. [18] Hashimoto S, Nakamura K, Oyama N, et al. Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J Dermatol Sci, 2006, 44(2): 93~99. [19] Mirshahpanah P, Li YY, Burkhardt N, et al. CCR4 and CCR10 ligands play additive roles in mouse contact hypersensitivity. Exp Dermatol, 2008, 17(1): 30~34. [20] Gros E, Bussmann C, Bieber T, et al. Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis. J Allergy Clin Immunol, 2009, 124(4): 753~760.